Motif Bio plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Motif Bio plc
Longer follow-up is part of regulatory path forward, the struggling antibiotics firm says after meeting with US FDA to discuss complete response letter.
The UK biotech is in dire need of further funding after US regulators requested an additional clinical trial for its much-delayed skin infection antibiotic.
A 3 May meeting with the FDA is likely to be crucial for the future commercialization strategy for the biotech’s precision-targeted antibacterial.
Keeping Track: US FDA Approves Esperoct, Tightens Chantix Label, Starts Review Of Alder’s CGRP Candidate
The latest drug development news and highlights from our US FDA Performance Tracker.
- Other Names / Subsidiaries
- Amphion Innovations plc
- Motif BioSciences inc.